1. Home
  2. ECPG vs NUVB Comparison

ECPG vs NUVB Comparison

Compare ECPG & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECPG
  • NUVB
  • Stock Information
  • Founded
  • ECPG 1998
  • NUVB 2018
  • Country
  • ECPG United States
  • NUVB United States
  • Employees
  • ECPG N/A
  • NUVB N/A
  • Industry
  • ECPG Finance Companies
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ECPG Finance
  • NUVB Health Care
  • Exchange
  • ECPG Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • ECPG 905.2M
  • NUVB 1.1B
  • IPO Year
  • ECPG 1999
  • NUVB N/A
  • Fundamental
  • Price
  • ECPG $44.65
  • NUVB $3.28
  • Analyst Decision
  • ECPG Strong Buy
  • NUVB Strong Buy
  • Analyst Count
  • ECPG 3
  • NUVB 6
  • Target Price
  • ECPG $62.67
  • NUVB $8.17
  • AVG Volume (30 Days)
  • ECPG 308.9K
  • NUVB 6.7M
  • Earning Date
  • ECPG 11-05-2025
  • NUVB 11-05-2025
  • Dividend Yield
  • ECPG N/A
  • NUVB N/A
  • EPS Growth
  • ECPG N/A
  • NUVB N/A
  • EPS
  • ECPG N/A
  • NUVB N/A
  • Revenue
  • ECPG $1,467,587,000.00
  • NUVB $14,355,000.00
  • Revenue This Year
  • ECPG $27.55
  • NUVB $332.80
  • Revenue Next Year
  • ECPG $5.84
  • NUVB $360.12
  • P/E Ratio
  • ECPG N/A
  • NUVB N/A
  • Revenue Growth
  • ECPG 15.50
  • NUVB 900.35
  • 52 Week Low
  • ECPG $26.45
  • NUVB $1.54
  • 52 Week High
  • ECPG $51.77
  • NUVB $4.09
  • Technical
  • Relative Strength Index (RSI)
  • ECPG 64.26
  • NUVB 58.18
  • Support Level
  • ECPG $43.02
  • NUVB $3.20
  • Resistance Level
  • ECPG $45.29
  • NUVB $3.41
  • Average True Range (ATR)
  • ECPG 1.20
  • NUVB 0.27
  • MACD
  • ECPG 0.10
  • NUVB -0.03
  • Stochastic Oscillator
  • ECPG 69.52
  • NUVB 33.55

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: